HEMOGENYX PHARM.PLC LS-01

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
G4R59S104
SEDOL
N/A
CIK
N/A
LEI:
FIGI: BBG00BDKH4D5
HEMO
HEMOGENYX PHARM.PLC LS-01
GICS: - · Sector: Cancer drugs · Sub-Sector: -
NAME
HEMOGENYX PHARM.PLC LS-01
ISIN
GB00BYX3WZ24
TICKER
HEMO
MIC
XLON
REUTERS
HEMO.L
BLOOMBERG
HEMO LN
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by AccessWire.

Fri, 22.11.2024       Hemogenyx Pharma
GB00BYX3WZ24

Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New Articles of Association LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group focused on developing new therapies ...
Read More
Hemogenyx Pharma
Technical Analysis Termsheet Terminal
Permalink
Fri, 22.11.2024       Hemogenyx Pharma
GB00BYX3WZ24

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company developing innovative therapies and treatments for blood diseases, is pleased to announce that the Institutional Review Board (IRB)of th...
Read More
Hemogenyx Pharma
Technical Analysis Termsheet Terminal
Permalink
Mon, 11.11.2024       Hemogenyx Pharma
GB00BYX3WZ24

Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical group focused on developing new therapies for bl...
Read More
Hemogenyx Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 30.10.2024       Hemogenyx Pharma
GB00BYX3WZ24

Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company focused on developing breakthrough therapies for blood diseases, is pleased to announce the schedule for the opening...
Read More
Hemogenyx Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 02.10.2024       Hemogenyx Pharma
GB00BYX3WZ24

Prevail Partners, LLC to invest again in Hemogenyx PharmaceuticalsPrevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study LONDON, UNITED KINGDOM / ACCESSWIRE / October 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments f...
Read More
Hemogenyx Pharma
Technical Analysis Termsheet Terminal
Permalink
Fri, 27.09.2024       Hemogenyx Pharma
GB00BYX3WZ24

LONDON, UNITED KINGDOM / ACCESSWIRE / September 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month per...
Read More
Hemogenyx Pharma
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements